Outcome of the meeting of the Board of Directors of Novartis India Limited held on Thursday, July, 23, 2026.

Novartis India Limited Inspire BKC 7th Floor, Bandra Kurla Complex Bandra East, Mumbai 400051 Maharashtra, India Tel +91 22 50243000 Website: www.novartis.in CIN- L24200MH1947PLC006104 Email: india.investors@novartis.com July 23, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 500672 Sub: Outcome of the Meeting of the Board of Directors of Novartis India Limited (“the Company”) held on Thursday, July 23, 2026. Dear Sir/ Madam, In continuation to our Board Meeting intimation dated Tuesday, July 07, 2026, and pursuant to Regulations 30 (read with Part A, Para A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) read with the relevant circulars issued by SEBI (‘SEBI Circular’), we hereby inform that the Board of Directors (‘Board’) of the Company in their Meeting held today i.e. Thursday, July 23, 2026, inter-alia have considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2026 and the Limited Review Report dated Thursday, July 23, 2026, as recommended by the Audit Committee, issued by the Statutory Auditors of the Company and the same is taken on record by the Board of the Company. The said Meeting commenced at 11.20 A.M. (IST) and concluded at 12.30 P.M. (IST). In terms of Regulation 33 of SEBI Listing Regulations, please find enclosed herewith: a) The Unaudited Financial Results for the quarter ended June 30, 2026 (Annexure-I). b) Limited Review Report dated Thursday, July 23, 2026, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and the same as taken on record by the Board of the Company (Annexure-II). The above is for your information and the same is also available on the website of the Company i.e. www.novartis.com/in-en/ Thanking you Yours sincerely, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer A60291 Encl.: as above.